| ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE | None | ||
| 5MG;100MG, 15MG;100MG |
Less Than $1000 mn
|
||
| None | None | ||
| None | None | ||
| None | None | ||
| STEGLUJAN is a combination of ertugliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, and sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. | |||
|
Yes
| |||
| STEGLUJAN | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| *** ********* | ||||||||||
| ********** **** **** ** * ********** *********-** ********* | ********** **** **** ** * ********** *********-** ********* | *****-*******[*.*.*]******-*,*,*-***** *********** | *****-*******[*.*.*]******-*,*,*-***** *********** | *****-*******[*.*.*]******-*,*,*-***** *********** | ****** ** ********** ******* **********, *** ******** ******* ******* | ****** ** ********** ******* **********, *** ******** ******* ******* | ****** ** ********** ******* **********, *** ******** ******* ******* | ****-***** ************ ********** ********* ********** *** *** ********* ** ********** ** ******** | ****-***** ************ ********** ********* ********** *** *** ********* ** ********** ** ******** |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|